Amgen Chief Executive KevinSharerKevin Sharer has hopes that a new drug, denosumab, could become a "double blockbuster, " both as a twice-a-year treatment for osteoporosis and as a remedy for cancers of the bone.
Amgen Chief Executive Kevin Sharer has hopes that a new drug, denosumab, could become a "double blockbuster, " both as a twice-a-year treatment for osteoporosis and as a remedy for cancers of the bone.